24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
@Finance
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
CytoReason
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
21:42
Zim $4.5 billion bidder faces foreclosure on his home
21:25
NextVision insiders cash out $200 million in share sale
21:14
"If an engineer in Ireland costs 20% less, it is clearly part of the consideration when deciding where to expand"
20:27
Electra Real Estate CEO: “The $7 trillion US rental housing market is the place to be”
More stories
Buzz
Most popular
Daily
Weekly
1
Jewish family from Mexico donates NIS 200 million to establish Israel's largest rehabilitation hospital
2
After raising $20 million, collapsed startup Swish.ai sells to Unframe for just $150,000
3
Echo: “Employees have become very good at identifying performative culture”
4
After PTSD and years of insomnia, Israeli founder raises $6.5 million to improve sleep through scent
5
More than 50 years after its debut, Israel's Kfir fighter jet gets a new lease on life
More news
CytoReason
4 stories about CytoReason
CytoReason raises $80 million, including from NVIDIA and Pfizer, to scale its AI disease models
17.07.24
|
Meir Orbach
The Israeli startup provides therapeutic area leaders with molecular-level insights and valuable AI tools to make data-driven decisions, helping them improve the probability of phase 2 success and optimize their R&D portfolio.
CytoReason raises $20 million from Pfizer for AI drug discovery and development platform
20.09.22
|
Meir Orbach
Pfizer will also have options to license the Israeli startup’s platform and disease models, and fund supplementary project support, in a deal potentially worth up to $110 million over the next five years
CytoReason enters Japanese market with SPI partnership
30.09.21
|
James Spiro
This is the first time that collaboration between an Israeli company and a Japanese pharmaceutical company has been announced to bring AI to clinical drug development
Pfizer Taps Israeli Machine Learning Drug Discovery Company CytoReason
10.01.19
|
Lilach Baumer
Under the agreement, CytoReason will receive payments "potentially equaling up to low double digit millions" of dollars